Shire-Nps Pharmaceuticals Stock Price, News & Analysis (NASDAQ:NPSP)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market Capitalization$4.99 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Shire-Nps Pharmaceuticals (NASDAQ:NPSP)

Shire-Nps Pharmaceuticals logoNPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Receive NPSP News and Ratings via Email

Sign-up to receive the latest news and ratings for NPSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorBio Therapeutic Drugs
SymbolNASDAQ:NPSP
CUSIP62936P10
Phone+1-908-4505300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.08)
Net IncomeN/A
Net Margins-2.96%
Return on Equity-5.98%
Return on Assets-2.77%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Frequently Asked Questions

What is Shire-Nps Pharmaceuticals' stock symbol?

Shire-Nps Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."

How were Shire-Nps Pharmaceuticals' earnings last quarter?

Shire-Nps Pharmaceuticals Inc (NASDAQ:NPSP) announced its quarterly earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company had revenue of $66.70 million for the quarter, compared to the consensus estimate of $69.30 million. Shire-Nps Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 5.98%. View Shire-Nps Pharmaceuticals' Earnings History.

Who are some of Shire-Nps Pharmaceuticals' key competitors?

How do I buy Shire-Nps Pharmaceuticals stock?

Shares of Shire-Nps Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Shire-Nps Pharmaceuticals?

Shire-Nps Pharmaceuticals has a market capitalization of $4.99 billion.

How can I contact Shire-Nps Pharmaceuticals?

Shire-Nps Pharmaceuticals' mailing address is 550 Hills Dr, BEDMINSTER, NJ 07921-1537, United States. The biopharmaceutical company can be reached via phone at +1-908-4505300.


MarketBeat Community Rating for Shire-Nps Pharmaceuticals (NPSP)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Shire-Nps Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Earnings History and Estimates Chart

Earnings by Quarter for Shire-Nps Pharmaceuticals (NASDAQ:NPSP)

Shire-Nps Pharmaceuticals (NASDAQ NPSP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/18/2015Q414$0.06($0.02)$69.30 million$66.70 millionViewN/AView Earnings Details
11/10/2014Q314$0.01($0.02)$59.50 million$57.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.01)$0.02$53.06 million$56.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.06)$48.30 million$44.04 millionViewListenView Earnings Details
2/18/2014Q413$0.02$0.07$44.22 million$54.45 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)($0.13)$31.62 million$36.50 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.13)($0.09)$27.56 million$25.43 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.09)($0.14)$28.93 million$27.10 millionViewListenView Earnings Details
11/9/2012Q312($0.16)($0.04)$28.18 million$27.02 millionViewN/AView Earnings Details
8/1/2012($0.09)$0.08ViewN/AView Earnings Details
5/3/2012($0.11)($0.12)ViewN/AView Earnings Details
2/15/2012($0.11)($0.10)ViewN/AView Earnings Details
11/3/2011($0.10)($0.14)ViewN/AView Earnings Details
8/2/2011($0.07)($0.07)ViewN/AView Earnings Details
5/3/2011($0.12)($0.13)ViewN/AView Earnings Details
2/15/2011($0.20)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Shire-Nps Pharmaceuticals (NASDAQ:NPSP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Shire-Nps Pharmaceuticals (NASDAQ NPSP) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Shire-Nps Pharmaceuticals (NASDAQ:NPSP)

Shire-Nps Pharmaceuticals (NASDAQ NPSP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/10/2015Susan E GrafVPSell6,711$45.87$307,833.57View SEC Filing  
12/17/2014Joseph J RogusSVPSell16,467$35.00$576,345.00View SEC Filing  
12/17/2014Luke M BesharCFOSell52,258$35.00$1,829,030.00View SEC Filing  
12/17/2014Rachel R SeliskerDirectorSell3,708$34.59$128,259.72View SEC Filing  
12/8/2014Rachel R SeliskerDirectorSell23,157$34.50$798,916.50View SEC Filing  
11/28/2014Rachel R SeliskerDirectorSell11,635$34.50$401,407.50View SEC Filing  
11/17/2014Joseph J RogusSVPSell26,782$30.00$803,460.00View SEC Filing  
11/11/2014Rachel R SeliskerDirectorSell15,188$29.50$448,046.00View SEC Filing  
10/31/2014Luke M BesharCFOSell10,000$29.00$290,000.00View SEC Filing  
10/27/2014Luke M BesharCFOSell30,635$26.75$819,486.25View SEC Filing  
2/13/2014Georges GemayelDirectorSell6,188$37.70$233,287.60View SEC Filing  
1/8/2014Luke BesharCFOSell31,588$35.01$1,105,895.88View SEC Filing  
12/26/2013Luke BesharCFOSell37,874$30.02$1,136,977.48View SEC Filing  
12/23/2013James GroningerDirectorSell3,000$29.50$88,500.00View SEC Filing  
12/18/2013Ed StratemeierSVPSell205,432$25.13$5,162,506.16View SEC Filing  
9/20/2013Luke BesharCFOSell50,000$30.26$1,513,000.00View SEC Filing  
9/16/2013Joseph RogusVPSell25,312$28.11$711,520.32View SEC Filing  
9/16/2013Luke BesharCFOSell50,000$27.89$1,394,500.00View SEC Filing  
8/30/2013Roger GarceauCMOSell110,000$25.18$2,769,800.00View SEC Filing  
8/20/2013James GroningerDirectorSell16,900$23.21$392,249.00View SEC Filing  
5/9/2013Luke M BesharCFOSell45,150$14.18$640,227.00View SEC Filing  
11/15/2012Glenn R MelroseSVPBuy11,000$9.09$99,990.00View SEC Filing  
10/3/2012Roger GarceauCMOSell140,625$9.51$1,337,343.75View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Shire-Nps Pharmaceuticals (NASDAQ NPSP) News Headlines

Source:
DateHeadline
Dicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical OfficerDicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical Officer
www.businesswire.com - June 8 at 9:48 AM
Syndax Pharmaceuticals (SNDX) Names Pierre Legault to Board of DirectorsSyndax Pharmaceuticals (SNDX) Names Pierre Legault to Board of Directors
www.streetinsider.com - January 6 at 2:13 AM
Syndax Adds Global Pharmaceutical Business Veteran to Board of DirectorsSyndax Adds Global Pharmaceutical Business Veteran to Board of Directors
globenewswire.com - January 5 at 9:02 PM
Shire (SHPG) Gets EU Nod for Label Expansion of RevestiveShire (SHPG) Gets EU Nod for Label Expansion of Revestive
www.zacks.com - July 8 at 6:34 PM
A Deep Dive Into Shires Business - Seeking AlphaA Deep Dive Into Shire's Business - Seeking Alpha
seekingalpha.com - May 30 at 4:40 PM
Company Overview of NPS Pharmaceuticals, Inc.Company Overview of NPS Pharmaceuticals, Inc.
www.bloomberg.com - April 11 at 10:07 PM
Smart-Money Healthcare Investing Focuses On Major Biotech Stocks - Seeking AlphaSmart-Money Healthcare Investing Focuses On Major Biotech Stocks - Seeking Alpha
seekingalpha.com - March 28 at 4:33 PM
NPS Pharmaceuticals, Inc. Company ProfileNPS Pharmaceuticals, Inc. Company Profile
biz.yahoo.com - February 25 at 4:46 PM
Shire Fourth-Quarter Earnings Exceed Analysts ExpectationShire Fourth-Quarter Earnings Exceed Analysts' Expectation
www.bloomberg.com - February 11 at 9:02 AM
Shire target NPS Pharma wins FDA approval for NatparaShire target NPS Pharma wins FDA approval for Natpara
uk.finance.yahoo.com - January 26 at 3:43 AM
Shire shares jump as drug approval vindicates $5.2 bln NPS purchaseShire shares jump as drug approval vindicates $5.2 bln NPS purchase
uk.finance.yahoo.com - January 26 at 3:16 AM
U.S. FDA approves NPS drug, in move validating Shire takeover dealU.S. FDA approves NPS drug, in move validating Shire takeover deal
uk.finance.yahoo.com - January 23 at 7:39 PM
[video]Jim Cramers Mad Money Recap: Blame Tech, Oil and Retail for Todays Losses[video]Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses
www.thestreet.com - January 12 at 8:32 PM
Shire acquires US rival NPS Pharmaceuticals for $5.2bnShire acquires US rival NPS Pharmaceuticals for $5.2bn
uk.finance.yahoo.com - January 12 at 8:18 AM
NPS a "natural fit" for pharma group Shire, says UBSNPS a "natural fit" for pharma group Shire, says UBS
uk.finance.yahoo.com - January 12 at 6:21 AM

SEC Filings

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Shire-Nps Pharmaceuticals (NASDAQ NPSP) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.